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Objectives The objectives of this study were to verify whether improvement in 6-min walk distance (6MWD) is associated
with clinical outcome in pulmonary arterial hypertension (PAH).
Background 6MWD is used as an endpoint to assess the benefit of therapies in PAH. However, whether changes in 6MWD
correlate with clinical outcome is unknown.
Methods Randomized trials assessing 6MWD in patients with PAH and reporting clinical endpoints were included in a
meta-analysis. The meta-analysis was performed to assess the influence of treatment on outcomes. Meta-
regression analysis was performed to test the relationship between 6MWD changes and outcomes.
Results Twenty-two trials enrolling 3,112 participants were included. Active treatments led to significant reduction of
all-cause death (odds ratio [OR]: 0.429; 95% confidence interval [CI]: 0.277 to 0.664; p  0.01), hospitalization
for PAH, and/or lung or heart-lung transplantation (OR: 0.442; 95% CI: 0.309 to 0.632; p  0.01), initiation of
PAH rescue therapy (OR: 0.555; 95% CI: 0.347 to 0.889; p  0.01), and composite outcome (OR: 0.400; 95%
CI: 0.313 to 0.510; p  0.01). No relationship between 6MWD changes and outcomes was detected.
Conclusions In patients with PAH, improvement in 6MWD does not reflect benefit in clinical outcomes. (J Am Coll Cardiol
2012;60:1192–201) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.083M
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ePulmonary arterial hypertension (PAH) is a progressive
disease leading to right-sided heart failure and poor survival
(1). In patients with PAH, 6-min walk distance (6MWD)
provides an assessment of exercise capacity and, similarly to
a cardiopulmonary test, independently predicts morbidity
and mortality (1–4).
Because limited functional capacity profoundly influences
the clinical status, changes in 6MWD have been employed
as an endpoint (often primary) in clinical studies conducted
for regulatory approval in patients with PAH of different
etiologies treated with different drugs (5–25). However,
although clinical events have generally been reported, no
study has been designed to verify whether changes in
6MWD reflect changes in clinical events. Yet this informa-
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Therefore, purpose of this study was to verify whether
improvement in 6MWD reflects incidence of clinical events
in patients with PAH.
Methods
Data sources and searches. The study was designed ac-
cording to PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) statement (26).
EDLINE, Cochrane, ISI Web of Science and SCOPUS
atabase were searched for articles published until August
011.
tudy selection. Study inclusion criteria were: report of
MWD at baseline and at end of follow-up, and of
ndpoints (all-cause death, hospitalization for PAH and/or
ung or heart-lung transplantation, initiation of PAH rescue
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September 25, 2012:1192–201 6-Min Walk Test and Clinical Eventstherapy); comparison of active drug treatment versus placebo
or of different doses of active drugs; randomized protocol
design. Studies were identified using the major medical subject
heading “pulmonary arterial hypertension” combined with the
following text and key words: 6-min walk test, 6MWD, 6-min
walk test, 6-min walk distance.
Data extraction and quality assessment. Two reviewers
independently screened articles for fulfillment of inclusion
criteria. Reviewers compared selected trials and discrepan-
cies were resolved by consensus. Baseline characteristics,
6MWD at baseline and end of follow-up and outcomes
including all-cause death, hospitalization for PAH and/or
lung or heart-lung transplantation and initiation of PAH
rescue therapy were abstracted. Rescue therapy was defined
as interruption of blindness status of patients enrolled in
clinical trials due to worsening clinical status. A composite
outcome including the above clinical outcomes was calcu-
lated and the assessment of the relationship between
6MWD changes and composite outcome represented the
primary objective of the study. Quality of trials was evalu-
ated by the Detsky method (27,28). Publication bias was
assessed using plots of study results against precision of the
study (funnel plots) for each outcome. Symmetry of the
funnel plots was tested using the Egger linear regression
method (29), Begg and Mazumdar rank correlation
method (30), and Macaskill modified test (31).
Figure 1 Meta-Analysis Flow Chart
6MWD  6-minute walk distanceOf 1,583 articles identified by
the initial search, 51 were re-
trieved for more detailed evalua-
tion, and 22 trials were included
in the study (Fig. 1).
Data synthesis and analysis.
Weighted random-effects meta-
regression analysis was performed
with the metareg command (27)
STATA version 11.0, Stata-
orps, College Station, Texas) to test the relationship between
MWD changes and incidence of CE. For this analysis, the
chieved differences between 6MWD changes (meters) in
ctive treatment and control groups (6MWD) were consid-
red. For assessment of the influence of potential effect
odifiers on the association between 6MWD changes and
utcomes, meta-regression analyses were conducted, including
he following covariates, each separately: mean age, sex,
ace, type of PAH, baseline functional class, 6MWD at
aseline and at end of follow-up, Detsky quality score,
uration of follow-up, study publication year,  mean
ulmonary artery pressure,  mean pulmonary vascular
esistance (PVR),  mean right atrial pressure, and 
ean cardiac index. For all meta-regression analyses, a
andom-effects model was used (27). Tau2 and the
restricted maximum likelihood methods were used to
Abbreviations
and Acronyms
6MWD  6-min walking
distance
PAH  pulmonary arterial
hypertension
PVR  pulmonary vascular
resistance
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6-Min Walk Test and Clinical Events September 25, 2012:1192–201explain residual heterogeneity not explained by potential
effect modifiers (27,32).
Outcome meta-analysis. Odds ratios (ORs) of the effect
f randomized treatments were calculated using the metan
ommand (STATA version 11.0, StataCorps). The choice
o use OR was driven by the retrospective design of the
eta-analysis based on published studies (27,33). Overall
stimates of effect were calculated with a fixed-effects
odel, random-effects model, or Peto method as appropri-
te (27). Statistical homogeneity was assessed using Q
Baseline Characteristics of Trials Included in Meta-AnalysisTable 1 Baseline Characteristics of Trials Included in Meta-Ana
First Author
(Ref. #)
Trial
Acronym Year
Treatment
Category Treatment
Badesch (5) 2007 PDE5 inhibitors Sildenafil 20 mg
Sildenafil 80 mg
Barst (6) PPHSG 1996 PGI2 analogues Epoprostenol
Barst (7) STRIDE-1 2004 ET-receptor
antagonists
Sitaxsentan 100 m
Sitaxsentan 300 m
Barst (8) STRIDE-2 2006 ET-receptor
antagonists
Sitaxsentan 50 mg
Sitaxsentan 100 m
Bosentan 125 mg
Galiè (9) ALPHABET 2002 PGI2 analogues Beraprost
Galiè (10) ARIES-1 2008 ET-receptor
antagonists
Ambrisentan 10 m
Ambrisentan 5 mg
Galiè (10) ARIES-2 2008 ET-receptor
antagonists
Ambrisentan 2.5 m
Ambrisentan 5 mg
Galiè (11) EARLY 2008 ET-receptor
antagonists
Bosentan
Galiè (12) PHIRST 2009 PDE5 inhibitors Tadalafil 10 mg
Tadalafil 2.5 mg
Tadalafil 20 mg
Tadalafil 40 mg
Galiè (13) SUPER 2005 PDE5 inhibitors Sildenafil 20 mg
Sildenafil 40 mg
Sildenafil 80 mg
Ghofrani (14) 2010 Other drug Imatinib  conven
therapy
Hiremath (15) TRUST 2010 PGI2 analogues Treprostinil
Humbert (16) BREATHE-2 2004 ET-receptor
antagonists
Bosentan 
epoprostenol
Jing (17) EVALUATION 2011 PDE5 inhibitors Vardenafil
Kawut (18) ASA-STAT 2011 Other drugs Aspirin  conventi
therapy
McLaughlin (19) STEP 2006 PGI2 analogues Iloprost  bosenta
Olschewski (20) AIR 2002 PGI2 analogues Iloprost
Oudiz (21) 2004 PGI2 analogues Treprostinil
Rubin (22) BREATHE-1 2002 ET-receptor
antagonists
Bosentan
Rubin (23) CIPPPH 1990 PGI2 analogues Epoprostenol
Simonneau (24) PACES 2008 PDE5 inhibitors Sildenafil 
epoprostenol
Wilkins (25) SERAPH 2005 PDE5 inhibitors Sildenafil  bosen
AIR Aerosolized Iloprost Randomized; ALPHABET Arterial Pulmonary Hypertension and Berapr
Placebo-Controlled, Multicenter, Efficacy; ASA-STAT Aspirin/Statins in PAH; BREATHE Bosenta
ypertension with Continous Intravenous Prostacyclin; EARLY  Endothelin Antagonist Trial in Mild
afety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension; PACES  Pulmonar
ypertension; PDE5 type 5 phosphodiesterase; PGI2 prostaglandin I2; PHIRST Pulmonary A
ERAPH Sildenafil Versus Endothelin Receptor Antagonist for Pulmonary Hypertension; STEP
o Relieve Impaired Exercise; SUPER  Sildenafil Use in Pulmonary Arterial Hypertension; TRUSTtatistic and further quantified with the I2 statistic. Thesignificance level for the overall estimates of effect and for
meta-regression analyses was set at p  0.05.
For verification of the robustness of the results, sensitivity
analysis were performed to test the influence of potential
effect modifiers including mean age, sex, race, type of PAH,
baseline functional class, 6MWD at baseline and at end of
follow-up, Detsky quality score, duration of follow-up,
study publication year,  mean pulmonary artery pressure,
PVR,  cardiac index, and  right atrial pressure. Finally,
for assessment of the potential influence of treatments on
Control
Treatment,
n
Control,
n
No. of
Patients
Age,
yrs
Placebo 21 22 43 54
Placebo 21 22 43 55
Conventional therapy 41 40 81 40
Placebo 55 60 115 47
Placebo 63 60 123 46
Placebo 62 62 124 55
Placebo 61 62 123 54
Placebo 60 62 122 51
Placebo 65 65 130 45
Placebo 67 67 134 48
Placebo 67 67 134 50
Placebo 64 65 129 51
Placebo 63 65 128 51
Placebo 93 92 185 45
Placebo 80 82 162 55
Placebo 82 82 164 54
Placebo 82 82 164 54
Placebo 79 82 161 54
Placebo 69 70 139 48
Placebo 67 70 137 50
Placebo 71 70 141 48
Placebo  conventional
therapy
28 31 59 44
Placebo 30 14 44 32
Placebo  epoprostenol 22 11 33 46
Placebo 44 20 64 31
Placebo  conventional
therapy
32 33 65 50
Placebo bosentan 34 33 67 50
Placebo 101 102 203 52
Placebo 41 49 90 51
Placebo 144 69 213 48
Conventional therapy 11 12 23 36
Epoprostenol 134 133 267 48
Bosentan 14 12 26 43
pean Trial; ARIES Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind,
omized trial of Endothelin Antagonist Therapy for PAH; CIPPPH Treatment of Primary Pulmonary
ptomatic Pulmonary Arterial Hypertension Patients; ET  endothelin; EVALUATION Efficacy and
ial Hypertension Combination Study of Epoprostenol and Sildenafil; PAH  pulmonary arterial
Hypertension and Response to Tadalafil; PPHSG Primary Pulmonary Hypertension Study Group;
nd Pilot Efficacy Trial in Combination With Bosentan for Evaluation in PAH; STRIDE Sitaxsentan
rostinil for Untreated Symptomatic PAH Trial.lysis
g
g
g
g
g
tional
onal
n
tan
ost Euro
n Rand
ly Sym
y Arter
rterialthe relationship between 6MWD and outcomes, meta-
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September 25, 2012:1192–201 6-Min Walk Test and Clinical Eventsregression analyses were performed for each treatment
category.
Results
Characteristics of included trials. Baseline characteristics
of trials included in the study are reported in Table 1. A
total of 335 clinical events were reported in 3,112 patients,
1,968 assigned to active treatments and 1,144 to control
group. Mean follow-up was 14.5  4.2 weeks (range 8 to
26.1 weeks). Mean age of patients was 58.2 6.2 years, and
ContinuedTable 1 Continued
Women,
%
White
Race, %
Idiopathic and/or
Familiar PAH, n%
Connective
Disease PAH, n%
Congenital Heart
Disease PAH, n%
79 NA 0 100 0
86 NA 0 100 0
73 NA 100 0 0
82 70 52 22 26
76 70 58 21 21
81 76 57 29 13
73 81 62 28 9
77 77 58 30 11
62 NA 48 10 18
84 69 76 41 0
86 71 78 35 0
71 81 84 38 0
74 85 83 42 0
70 91 61 18 17
81 84 65 24 8
81 84 65 24 8
77 81 63 23 8
77 84 62 22 11
76 86 78 31 7
76 87 78 31 7
80 84 79 30 7
51 93 81 10 NA
61 0 95 5 0
70 85 82 18 0
83 NA 61 30 9
86 60 55 32 9
79 81 55 NA NA
67 NA 50 17 NA
90 NA 0 100 0
79 80 70 30 0
70 NA 100 0 0
80 79 79 17 NA
81 85 88 12 076.1% were women. 0Outcome analysis. Active treatments led to significant
reduction of the composite outcome without heterogeneity
among studies (OR: 0.400; 95% confidence intervals [CI]:
0.313 to 0.510; comparison p  0.01, heterogeneity p 
0.345) (Fig. 2). Additionally, each component of the com-
posite outcome was significantly reduced by treatments,
including all-cause death (OR: 0.429; 95% CI: 0.277 to
0.664; comparison p  0.01, heterogeneity p  0.796)
(Online Fig. 1), hospitalization for PAH and/or lung or
eart-lung transplantation (OR: 0.442; 95% CI: 0.309 to
ctional
ss I, %
Functional
Class II, %
Functional
Class III, %
Functional
Class IV, %
Follow-Up,
weeks
Detsky Quality
Score
0 37 60 2 12 18
0 42 58 0 12 18
0 0 74 26 12 17
0 33 65 2 12 17
0 35 63 2 12 17
0 35 59 6 18 19
0 40 56 4 18 19
0 37 59 4 18 19
0 49 51 0 12 19
3 34 57 6 12 18
2 32 60 5 12 18
2 45 51 2 12 18
2 41 55 2 12 18
0 100 0 0 26 19
1 29 68 2 16 19
1 29 68 2 16 19
1 31 67 1 16 19
2 30 66 1 16 19
1 40 53 6 12 19
1 40 57 2 12 19
1 43 54 3 12 19
0 31 61 5 24 20
0 0 95 5 12 17
0 0 76 24 16 19
0 47 53 0 12 19
8 63 29 0 26 20
0 1 97 4 12 19
0 0 59 41 12 16
0 10 74 16 12 18
0 0 92 8 12 19
NA NA NA NA 8 17
1 25 66 6 16 19
NA NA NA NA 16 18Fun
Cla.632; comparison p  0.01, heterogeneity p  0.838)
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6-Min Walk Test and Clinical Events September 25, 2012:1192–201Figure 2 OR Estimate of Composite Outcome in Active Treatment Groups Compared With Control Groups
See Table 1 for trial acronym definitions. CI  confidence interval; OR  odds ratio.Exp(b) of 6MWD Change From Baseline for Each Outcome in Pooled Data Analysis and Each Treatment Category GroupTable 2 Exp(b) of 6MWD Change From Baseline for Each Outcome in Pooled Data Analysis and Each Treatment Category Group
Outcome Exp(b) SE 95% CI Change in Tau2 p Tau REML
Pooled data analysis
All-cause death 0.04 0.03 0.09 to 0.01 1.62 0.117 0
Hospitalization for PAH and/or lung or heart-lung transplantation 0.07 0.04 0.17 to 0.02 1.66 0.113 0
Initiation of PAH rescue therapy 0.03 0.05 0.14 to 0.07 0.69 0.50 0.06
Composite outcome 0.05 0.03 0.11 to 0.01 1.71 0.097 0.11
PDE5 inhibitor treatment group
All-cause death 0.04 0.09 0.24 to 0.16 0.44 0.67 0
Hospitalization for PAH and/or lung or heart-lung transplantation 0.16 0.07 0.31 to0.00 2.33 0.048 0
Initiation of PAH rescue therapy 0.09 0.13 0.40 to 0.22 0.69 0.52 1.33
Composite outcome 0.09 0.07 0.25 to 0.06 1.36 0.20 0.41
ET receptor antagonists treatment group
All-cause death 0.10 0.07 0.27 to 0.08 1.43 0.21 0
Hospitalization for PAH and/or lung or heart-lung transplantation 0.03 0.08 0.23 to 0.16 0.37 0.72 0
Initiation of PAH rescue therapy 0.03 0.15 0.45 to 0.39 0.20 0.85 0
Composite outcome 0.07 0.05 0.18 to 0.04 1.44 0.181 0
PGI2 analogues
All-cause death 0.01 0.04 0.14 to 0.12 0.21 0.85 0
Hospitalization for PAH and/or lung or heart-lung transplantation NA NA NA NA NA NA
Initiation of PAH rescue therapy NA NA NA NA NA NA
Composite outcome 0.12 0.10 0.39 to 0.15 1.24 0.28 0.156MWD  6-min walk distance; CI  confidence intervals; NA  not available (because of small number of studies using this treatment category); REML  restricted maximum likelihood; SE  standard
error; other abbreviations as in Table 1.
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September 25, 2012:1192–201 6-Min Walk Test and Clinical Events(Online Fig. 2), and initiation of PAH rescue therapy (OR:
0.555; 95% CI: 0.347 to 0.889; comparison p  0.01,
heterogeneity p  0.648) (Online Fig. 3).
Meta-regression analysis. Meta-regression analysis
showed no relationship between 6MWD and composite
outcome. Additionally, no relationship was found be-
tween 6MWD and single components of the composite
outcome (Tables 2 and 3, Fig. 3). From 12 studies
5–7,11,13,14,16,17,19,20,23,24) reporting changes in pul-
onary hemodynamics (Table 4), a significant correlation
as found between 6MWD and PVR (r0.630; p
.009).
ensitivity analysis. Results were mostly confirmed when
otential effect modifiers were introduced as covariates in
he meta-regression analysis. Only baseline 6MWD in-
uenced the relationship between 6MWD and hospi-
alization for PAH and/or lung or heart-lung transplan-
ation with borderline statistical significance (p  0.042)
6-Min Walk Distance ValuesTable 3 6-Min Walk Distance Values
First Author (Ref. #) Trial Acronym Year
6MWD a
Treatment, m
Badesch (5) 2007 336
Bart (6) PPHSG 1996 349
316
Barst (7) STRIDE-1 2004 394
Barst (8) STRIDE-2 2006 387
328
360
337
Galiè (9) ALPHABET 2002 362
Galiè (10) ARIES-1 2008 341
340
Galiè (10) ARIES-2 2008 347
355
Galiè (11) EARLY 2008 438
Galiè (12) PHIRST 2009 338
Galiè (13) SUPER 2005 347
338
352
347
345
339
Ghofrani (14) 2010 392
Hiremath (15) TRUST 2010 259
Humbert (16) BREATHE-2 2004 285
Jing (17) EVALUATION 2011 295
Kawut (18) ASA-STAT 2011 447
McLaughlin (19) STEP 2006 336
Olschewski (20) AIR 2002 332
Oudiz (21) 2004 280
Rubin (22) BREATHE-1 2002 330
Rubin (23) CIPPPH 1990 246
Simonneau (24) PACES 2008 349
Wilkins (25) SERAPH 2005 290
Abbreviations as in Tables 1 and 2.Table 5), whereas no significant influence was found on mhe composite outcome, all-cause death, or initiation of
AH rescue therapy. In the type 5 phosphodiesterase
nhibitor treatment group, the relationship between
6MWD and hospitalization for PAH and/or lung or
eart-lung transplantation was of borderline significance
p  0.048) (Table 2).
ublication bias. No publication bias was detected for
omposite or single outcome analysis.
iscussion
mprovement of 6MWD is a valuable goal in patients
ith PAH in whom functional capacity is severely
ompromised (5–25). The present study assessed whether
hanges in 6MWD also reflect prognosis and indicated
hat they do not predict reduction of major clinical events
nduced by therapies in a short-term follow-up (3 to 4
line, Mean 6MWD Changes at End of Study, Mean
 6MWD, %Control, m Treatment, m Control, m
334 42 13 16.4
334 15 13 8.2
272 32 15 16.0
413 22 13 8.7
413 20 13 8.2
321 18 6 7.5
321 25 6 9.2
321 23 6 9.0
383 15 9 6.4
342 NA NA 14.9
342 NA NA 9.1
343 NA NA 9.3
343 NA NA 16.9
431 11 8 4.4
343 NA NA 5.9
343 NA NA 4.0
343 NA NA 7.9
343 NA NA 9.5
344 NA NA 13.0
344 NA NA 13.3
344 NA NA 14.6
369 22 1 6.0
231 67 25 37.0
305 43 72 10.0
388 60 9 21.3
418 9 20 6.8
340 30 4 7.7
315 NA NA 11.2
296 24 3 7.3
344 36 8 13.1
205 132 87 20.0
342 30 1 8.3
305 75 59 5.4t Baseonths).
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6-Min Walk Test and Clinical Events September 25, 2012:1192–201A substantial reduction of all-cause mortality, hospital-
ization and/or lung or heart-lung transplantation, and
initiation of rescue therapy in treated patients was shown at
a mean follow-up of 14.5 weeks, consistent with a recent
meta-analysis for the first time reporting a favorable effect of
therapies on mortality and morbidity in patients with PAH
(34). However, long-term mortality remains high as re-
ported in registry studies and emphasizes the need for
longer prospective trials (35).
Parameters reflecting prognosis in patients with PAH
ould be useful for future clinical trials (1). From our
ndings, changes in 6MWD do not reflect clinical event
ccurrence and should therefore only be considered
escriptive of the effects of therapies on functional status.
otably, lack of association with 6MWD changes was
ound for the composite outcome and for each single
omponent. In fact, it has been reported that threshold
Figure 3 Meta-Regression Analysis
Meta-regression between (A) 6MWD and composite outcome, (B) all-cause deat
and/or lung or heart-lung transplantation, (D) and initiation of PAH rescue therapyalues of 6MWD, rather than changes induced by ther- cpies, are prognostic predictors, with mortality higher in
atients with 6MWD  250 m and substantially lower
n patients with 6MWD 440 m (4,6). Thus, despite
hanges induced by therapies, absolute values may remain
elow the high-risk threshold or improvement may occur
n patients with preserved 6MWD capacity, explaining
he reduced prognostic value of changes in 6MWD.
ssociation between changes in 6MWD and clinical and
emodynamic status. Most clinical trials reporting
MWD as primary endpoint also assessed clinical status
nd pulmonary hemodynamic parameters. In some of
hese trials (5–7,13,17,20,24), 6MWD improvement was
aralleled by improvement of hemodynamic parameters,
hereas other studies (9,11,14,19,21) failed to demon-
trate consensual changes in 6MWD and hemodynamic
tatus. Interestingly, in the present study, pooling data
ndicated a significant inverse correlation between
hospitalization for pulmonary arterial hypertension (PAH)
D: 6-minute walking distanceh, (C)
. 6MWhanges in 6MWD and changes in PVR, as previously
nce; RA
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September 25, 2012:1192–201 6-Min Walk Test and Clinical Eventsreported by Barst et al. (6). Furthermore, 6MWD
changes also did not invariably reflect the effects of
treatments on clinical status, assessed by New York Heart
Association functional class, Borg dyspnea index, or time
to clinical worsening (9,12,13,24).
Explanations for these observations can only be hy-
pothesized. Because clinical trials do not explore patho-
physiological mechanisms of endpoint changes, whether
improvement of 6MWD arises from favorable resting or
exercise hemodynamic changes (i.e., from mechanisms
expected to have an impact on prognosis) remains un-
proven. Alternatively, improvement of skeletal blood flow
without changes in pulmonary hemodynamics may also
account for improvement of 6MWD, but no impact on
prognosis would be expected in this case (36). Therefore,
studies aimed at elucidating the mechanisms of improve-
ment in 6MWD would be much warranted to further
assess the relationship between functional capacity and
outcomes. Furthermore, the relatively short follow-up of
Hemodynamic ValuesTable 4 Hemodynamic Values
First Author (Ref. #) Trial Acronym P
Badesch (5) 2
Barst (6) PPHSG 1
3
Barst (7) STRIDE-1 2
Barst (8) STRIDE-2 2
N
N
N
Galiè (9) ALPHABET N
Galiè (10) ARIES-1 N
N
Galiè (10) ARIES-2 N
Galiè (11) EARLY N
2
Galiè (12) PHIRST N
Galiè (13) SUPER N
N
N
1
1
3
Ghofrani (14) 2
Hiremath (15) TRUST N
Humbert (16) BREATHE-2 1
Jing (17) EVALUATION 2
Kawut (18) ASA-STAT N
McLaughlin (19) STEP 3
Olschewski (20) AIR 3
Oudiz (21) N
Rubin (22) BREATHE-1 N
Rubim (23) CIPPPH 3
Simonneau (24) PACES 2
Wilkins (25) SERAPH N
PAP  pulmonary artery pressure; PVR  pulmonary vascular resistaclinical trials included in the meta-analysis prevented theevaluation of whether a significant association could be
found at longer follow-up.
Study limitations. The current meta-analysis was not
patient level and therefore results should be considered
provisional. Although sensitivity analysis enhanced the
robustness of our findings, confirmation from a patient-
level analysis would be worthwhile. In addition, none of
the studies reported clinical events as a primary endpoint
and although no significant heterogeneity was found in
the outcome analysis, the possibility that results may not
apply to all categories of patients with PAH cannot be
excluded. Finally, lack of standardization and suboptimal
reproducibility of the test may also hamper the associa-
tion between 6MWD changes and outcomes.
Conclusions
In patients with PAH, pharmacological treatments im-
proved functional capacity and reduced mortality and mor-
PAP RAP
 Mean
Cardiac Index
12.26 14.66 NA
10.21 4.69 NA
11.16 18.40 24.40
5.67 13.29 12.50
9.43 23.49 17.03
NA NA NA
NA NA NA
NA NA NA
3.36 11.76 8.33
NA NA NA
NA NA NA
NA NA NA
NA NA NA
10.88 8.33 8.89
NA NA NA
NA NA NA
NA NA NA
NA NA NA
4.91 12.93 10.00
6.09 15.55 11.56
9.82 14.44 16.59
9.93 NA NA
NA NA NA
6.68 18.49 11.76
8.82 22.30 17.44
NA NA NA
15.54 NA NA
8.25 NA NA
3.73 26.19 14.28
NA NA NA
3.59 NA NA
7.55 NA NA
NA NA NA
P  right atrial pressure; other abbreviation as in Tables 1 and 2.VR
4.57
6.99
0.62
7.95
6.16
A
A
A
A
A
A
A
A
0.35
A
A
A
A
6.78
9.96
1.50
6.14
A
2.68
9.96
A
0.54
2.37
A
A
5.58
4.82
Abidity in the short term. However, favorable effects on
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6-Min Walk Test and Clinical Events September 25, 2012:1192–201clinical events were not predicted by changes in 6MWD.
Further studies are warranted to define mechanisms of
functional changes induced by therapies and their value as
markers of disease modification in PAH.
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Po ential Effect Modifier f
6MWD With Change in Tau2 and
Statistical Significance for Each Outcome
6MWD
Change in Tau2 p Value
All-cause death
Year of publication 1.60 0.123
Women 1.71 0.101
Age 0.69 0.50
White race 0.04 0.97
Idiopathic and/or familiar PAH 1.29 0.21
Connective disease PAH 1.33 0.197
Congenital heart disease PAH 1.59 0.128
Duration of follow-up 1.31 0.20
Functional class I 1.85 0.079
Functional class II 1.04 0.31
Functional class III 1.09 0.29
Functional class IV 1.58 0.129
Mean 6MWD baseline 1.25 0.22
Mean 6MWD at the end of follow-up 1.60 0.12
Detsky quality score 1.05 0.30
Mean pulmonary vascular resistance 0.52 0.61
Mean pulmonary artery pressure 1.34 0.21
Mean cardiac index 0.75 0.487
Mean right atrial pressure 1.27 0.243
Hospitalization for PAH and/or lung or
lung-heart transplantation
Year of publication 1.41 0.174
Women 1.50 0.149
Age 1.78 0.091
White race 1.71 0.104
Idiopathic and/or familiar PAH 1.96 0.065
Connective disease PAH 1.26 0.22
Congenital heart disease PAH 1.63 0.121
Duration of follow-up 1.30 0.21
Functional class I 1.30 0.21
Functional class II 1.51 0.149
Functional class III 1.46 0.161
Functional class IV 1.53 0.142
Mean 6MWD baseline 2.18 0.042
Mean 6MWD at the end of follow-up 1.60 0.12
Detsky quality score 1.90 0.073
Mean pulmonary vascular resistance 1.04 0.34
Mean pulmonary artery pressure 1.09 0.32
Mean cardiac index 0.37 0.74
Mean right atrial pressure 0.25 0.82
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